Development of a Selective CDK 7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype Graphical

[1]  Charles Y. Lin,et al.  Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype. , 2019, Cell chemical biology.

[2]  P. Sorger,et al.  DeepDyeDrop: an image-based approach to quantify the phenotypic response of cancer cells to therapeutics (Conference Presentation) , 2018 .

[3]  P. Hammerman,et al.  Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors. , 2017, Cell chemical biology.

[4]  Heiner Koch,et al.  The target landscape of clinical kinase drugs , 2017, Science.

[5]  R. Young,et al.  Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors. , 2017, Cell reports.

[6]  Jarrod A. Marto,et al.  mzStudio: A Dynamic Digital Canvas for User-Driven Interrogation of Mass Spectrometry Data , 2017, Proteomes.

[7]  William M Alexander,et al.  multiplierz v2.0: A Python‐based ecosystem for shared access and analysis of native mass spectrometry data , 2017, Proteomics.

[8]  Jeremy R. Jacobsen,et al.  Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications. , 2017, Cell reports.

[9]  P. Sorger,et al.  Structure-guided development of covalent TAK1 inhibitors. , 2017, Bioorganic & medicinal chemistry.

[10]  J. Taunton,et al.  Engineered Covalent Inactivation of TFIIH-Kinase Reveals an Elongation Checkpoint and Results in Widespread mRNA Stabilization. , 2016, Molecular cell.

[11]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[12]  Christopher C. Ebmeier,et al.  Identification of Mediator Kinase Substrates in Human Cells using Cortistatin A and Quantitative Phosphoproteomics. , 2016, Cell reports.

[13]  M. Geyer,et al.  Structural and Functional Analysis of the Cdk13/Cyclin K Complex. , 2016, Cell reports.

[14]  D. Price,et al.  THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing. , 2015, Molecular cell.

[15]  K. Hoeflich,et al.  Inhibitors of p21-activated kinases (PAKs). , 2015, Journal of medicinal chemistry.

[16]  Fei Chen,et al.  Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolide , 2015, Genes & development.

[17]  Doris Chen,et al.  Megabase-scale deletion using CRISPR/Cas9 to generate a fully haploid human cell line , 2014, Genome research.

[18]  T. Albert,et al.  Cyclin-Dependent Kinase 7 Controls mRNA Synthesis by Affecting Stability of Preinitiation Complexes, Leading to Altered Gene Expression, Cell Cycle Progression, and Survival of Tumor Cells , 2014, Molecular and Cellular Biology.

[19]  Sridhar Ramaswamy,et al.  Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.

[20]  D. Eick,et al.  The structure and substrate specificity of human Cdk12/Cyclin K , 2014, Nature Communications.

[21]  G. Canevari,et al.  Structural insight into maternal embryonic leucine zipper kinase (MELK) conformation and inhibition toward structure-based drug design. , 2013, Biochemistry.

[22]  L. Hengst,et al.  CDK4 T172 Phosphorylation Is Central in a CDK7-Dependent Bidirectional CDK4/CDK2 Interplay Mediated by p21 Phosphorylation at the Restriction Point , 2013, PLoS genetics.

[23]  Karl A. Merrick,et al.  A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. , 2013, Molecular cell.

[24]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[25]  Chao Zhang,et al.  Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II , 2012, Nature Structural &Molecular Biology.

[26]  D. Bouzida,et al.  Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. , 2012, Journal of medicinal chemistry.

[27]  Taebo Sim,et al.  Discovery of potent and selective covalent inhibitors of JNK. , 2012, Chemistry & biology.

[28]  Imre Berger,et al.  MultiBac: expanding the research toolbox for multiprotein complexes , 2011, Trends in Biochemical Sciences.

[29]  N. Gray,et al.  In situ kinase profiling reveals functionally relevant properties of native kinases. , 2011, Chemistry & biology.

[30]  G. Calin,et al.  Regulation of tumor angiogenesis by EZH2. , 2010, Cancer cell.

[31]  D. Knighton,et al.  Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth , 2010, Proceedings of the National Academy of Sciences.

[32]  S. Buratowski.  Progression through the RNA polymerase II CTD cycle. , 2009, Molecular cell.

[33]  P. Kaldis,et al.  Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms , 2009, Oncogene.

[34]  Chao Zhang,et al.  TFIIH-Associated Cdk7 Kinase Functions in Phosphorylation of C-Terminal Domain Ser7 Residues, Promoter-Proximal Pausing, and Termination by RNA Polymerase II , 2009, Molecular and Cellular Biology.

[35]  J. Snyder,et al.  The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. , 2009, Cancer research.

[36]  Dirk Eick,et al.  TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. , 2009, Molecular cell.

[37]  Jignesh R. Parikh,et al.  mzAPI: a new strategy for efficiently sharing mass spectrometry data , 2009, Nature Methods.

[38]  S. Ficarro,et al.  Improved electrospray ionization efficiency compensates for diminished chromatographic resolution and enables proteomics analysis of tyrosine signaling in embryonic stem cells. , 2009, Analytical chemistry.

[39]  W. Janzen,et al.  High-throughput screening of the cyclic AMP-dependent protein kinase (PKA) using the caliper microfluidic platform. , 2009, Methods in molecular biology.

[40]  Shona Murphy,et al.  Cracking the RNA polymerase II CTD code. , 2008, Trends in genetics : TIG.

[41]  R. Fisher,et al.  The CDK-Activating Kinase (CAK) Csk1 Is Required for Normal Levels of Homologous Recombination and Resistance to DNA Damage in Fission Yeast , 2008, PloS one.

[42]  A. Viale,et al.  Chemical inhibition of the TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis , 2007, Proceedings of the National Academy of Sciences.

[43]  Stéphane Larochelle,et al.  Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. , 2007, Molecular cell.

[44]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[46]  D. N. Perkins,et al.  Probability‐based protein identification by searching sequence databases using mass spectrometry data , 1999, Electrophoresis.

[47]  M. Vigneron,et al.  Transcription-independent phosphorylation of the RNA polymerase II C-terminal domain (CTD) involves ERK kinases (MEK1/2). , 1999, Nucleic acids research.

[48]  J. Pines,et al.  Human Cyclin a Is Required for Mitosis until Mid Prophase , 1999, The Journal of cell biology.

[49]  James M. Roberts,et al.  CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.

[50]  D. Price,et al.  Control of RNA Polymerase II Elongation Potential by a Novel Carboxyl-terminal Domain Kinase* , 1996, The Journal of Biological Chemistry.

[51]  P. Kuzmič,et al.  Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. , 1996, Analytical biochemistry.

[52]  E. Nigg,et al.  MAT1, cdk7 and cyclin H form a kinase complex which is UV light‐sensitive upon association with TFIIH. , 1996, The EMBO journal.

[53]  J. Labbé,et al.  MAT1 (‘menage à trois’) a new RING finger protein subunit stabilizing cyclin H‐cdk7 complexes in starfish and Xenopus CAK. , 1995, The EMBO journal.

[54]  D. Reinberg,et al.  Cdk-activating kinase complex is a component of human transcription factor TFIIH , 1995, Nature.

[55]  R. Young,et al.  Association of Cdk-activating kinase subunits with transcription factor TFIIH , 1995, Nature.

[56]  R. Kurzrock,et al.  KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts. , 1995, Leukemia.

[57]  R. Kornberg,et al.  Relationship of CDK-activating kinase and RNA polymerase II CTD kinase TFIIH/TFIIK , 1994, Cell.

[58]  David O. Morgan,et al.  A novel cyclin associates with M015/CDK7 to form the CDK-activating kinase , 1994, Cell.

[59]  R. Conaway,et al.  Phosphorylation of C-terminal domain of RNA polymerase II is not required in basal transcription , 1993, Nature.

[60]  M. Levandowsky,et al.  Distance between Sets , 1971, Nature.